Lykos Therapeutics may have shed three-quarters of its staff in the wake of the FDA's rejection of its MDMA candidate for ...

In a short statement Friday, Lykos Therapeutics expressed optimism about a recent meeting with the regulator to discuss next ...

The FDA has indicated a path forward for the first psychedelic-assisted therapy, its developer which failed to win approval ...

Lykos Therapeutics said it had a “productive” meeting with the FDA to discuss a path forward for its recently rejected PTSD ...

After the turbulent reaction to Lykos Therapeutics’ failure to get its MDMA formulation approved, clinicians and industry ...

The fallout from the FDA's recent decision not to approve Lykos Therapeutics' psychedelic treatment has spread to its senior management, with chief executive Amy Emerson stepping down. Emerson has ...

(Bloomberg) -- Lykos Therapeutics Inc. Chief Executive Officer Amy Emerson stepped down weeks after US regulators rejected ...

Lykos Therapeutics is slashing around 75% of its staff following the FDA's decision not to approve its MDMA-assisted therapy for post-traumatic stress disorder (PTSD) last week, with founder Rick ...

Recommended Reading In tone-setting verdict, FDA rejects MDMA as a therapy aid for PTSD The CEO of Lykos Therapeutics will step down after the company’s efforts to win a milestone approval for ...

The FDA has previously acknowledged its therapeutic potential, granting a new drug application, submitted by Lykos Therapeutics (formerly MAPS Public Benefit Corporation), priority review for ...

(Reuters) - Lykos Therapeutics said on Thursday longtime CEO Amy Emerson would step down from the role, in the latest shakeup after the U.S. health regulator declined to approve its MDMA-based ...

An FDA advisory panel voted against recommending the use of MDMA in PTSD therapy. The rejection of Lykos Therapeutics' treatment hurt stocks of firms with similar therapies in development.